- 01Raise: $904k via placement.
- 02New shares: 45.2m @ $0.02.
- 03Options: 90.4m @ $0.04 (2y); 5m to lead mgr.
- 04Use: advance reformulated drugs; IP/regulatory work.
EVE Health Group (ASX: EVE) has raised $904,000 through a placement to sophisticated and professional investors to support the advancement of its reformulated pharmaceutical development strategy.
A total of 45.2 million new fully paid ordinary shares will be issued at a price of $0.02 per share.
Subject to shareholder approval, investors will also receive 90.4 million unlisted options exercisable at $0.04 and expiring two years from issue, while a further 5 million options will be issued to the lead manager.
Settlement and allotment of the placement securities are expected to occur on 19 March 2026.
Reformulation Strategy Targets
EVE Health is developing reformulated versions of established pharmaceutical compounds using proprietary drug delivery and solubilisation technologies designed to improve bioavailability, onset of action, and patient convenience.
The funds raised will be directed toward advancing these candidates and supporting intellectual property and regulatory activities.
The company is targeting large global therapeutic markets including sexual health therapies and cardiovascular treatments.
These programs utilise well-established pharmaceutical active ingredients with known safety profiles while introducing novel delivery systems and intellectual property protection.
Improved Delivery Formats
Chief operating officer Ben Rohr said the capital raising would support the company’s ongoing strategy targeting global markets.
The improved delivery formats may provide differentiated products capable of commercialisation through licensing or supply partnerships leveraging the regulatory, manufacturing, and distribution capabilities of larger pharmaceutical groups.
“Our focus is on improving the delivery and usability of well-established medicines as they approach patent expiry, creating opportunities to develop differentiated products with strong commercial potential,” Mr Rohr said.
“The additional funding allows the company to progress intellectual property protection and further development activities […] as we continue exploring licensing and partnership opportunities with established pharmaceutical companies.”
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.